Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Goldman Sachs used derivatives to help Exor build $2.8 billion Philips stake, filings show

Published 08/17/2023, 04:16 AM
Updated 08/17/2023, 04:20 AM
© Reuters. FILE PHOTO: The entrance to Philips Healthcare's headquarters in Best, Netherlands, August 30, 2018. REUTERS/Piroschka van de Wouw/File Photo

By Toby Sterling, Pablo Mayo Cerqueiro and Andres Gonzalez

AMSTERDAM (Reuters) - Investment company Exor (OTC:EXXRF) was able to build a 15% stake in Dutch healthcare group Philips without triggering the usual disclosures thanks to derivatives deals through Goldman Sachs (NYSE:GS), regulatory filings show.

The two companies said earlier this week that Exor (AS:EXOR), the investment arm of Italy's Agnelli family, had become the biggest shareholder in Philips by buying 15% of the company for about $2.8 billion.

Exor's investment was seen as a vote of confidence in Philips (AS:PHG) and boosted the Dutch company's shares. But the transaction was carried out without triggering disclosures normally required under Dutch financial market rules if a company accumulates a stake of more than 3%, 5%, 10%, or 15% in a Dutch company.

When asked about this by reporters, Philips CEO Roy Jakobs said Exor had used a "construct with a financial institution" but gave no further details.

A US Securities and Exchange Commission filing published earlier this week showed that Exor had first purchased a stake of 2.99% in Philips by June 30 -- just under the reporting threshold.

Filings by the Dutch Financial Market Authority AFM dated Aug. 14 but published late on Wednesday showed Goldman Sachs had taken an 12.11% stake in Philips using a derivatives structure that included 95 million call options.

Sources confirmed to Reuters earlier this week that Goldman Sachs acted on behalf of Exor but could not give more details.

Exor and Goldman Sachs declined to comment.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Law firm Allen & Overy acted as Exor's legal adviser on the deal, the sources said. Law firm De Brauw confirmed it advised Philips. An Allen & Overy spokesperson did not immediately respond to a request for comment.

An AFM spokesperson confirmed, without reference to the Exor deal, that there is no legal obstacle to an investor jumping various thresholds in terms of accumulating a shareholding in a single day.

Philips welcomed Exor's investment and the companies signed an agreement over the weekend that Exor would commit to not raising its stake further than 20%, eliminating the possibility of a full takeover attempt.

 

 

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.